The imidazo[2,1-b][1,3]thiazine nucleus, as well as the pyridine-N-oxide fragment, are pharmacophore groups that have received much attention from researchers. That is why the combination of these scaffolds in the structure of a single molecule seems to be quite attractive from chemical and biological point of view. Synthetically available 4-pyridinyloxy-substituted (benzo)imidazo[2,1-b]thiazines were used as precursors to obtain previously unknown (benzo)imidazo[2,1-b][1,3]thiazin-6-yloxypyridine 1-oxides. It was found that the oxidation of the latter with m-chlorobenzoic acid under mild reaction conditions using dichloromethane as a solvent at room temperature proceeds smoothly and selectively to obtain only the target products. The composition and structure of the synthesized pyridine-N-oxides are unambiguously confirmed by complex physicochemical analysis, particularly by 1H and 13C NMR spectroscopy, chromato-mass spectrometry, as well as elemental analysis data. The antiexudative activity of (benz)imidazo[2,1-b][1,3]thiazin-6-yloxypyridine 1-oxides was studied in vivo in a model of carrageenan-induced paw edema in white outbred male rats. The development of edema was considered from increasing the volume of the paw 4 hours after the introduction of carrageenan. Quantitative assessment of antiexudative activity was performed by the degree of reduction of rat paw edema, and the rate of suppression of the inflammatory process was calculated. Performed bioscreening showed that the synthesized pyridine-N-oxides are characterized by weak anti-inflammatory activity, and only 2-chloro-4-[(2,3-diphenyl-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazin-6-yl)oxy]pyridine 1-oxide 2a has moderate antiexudative effect with of inflammatory inhibition rate of 31.9%. This compound is thus of interest for further structural modification in order to obtain potential non-steroidal anti-inflammatory agents. It is important to note that the presence in the structure of the synthesized derivatives 2a-e of N-oxide fragment is very promising for the design of anti-inflammatory agents, which are characterized by the absence of side effects caused by inhibition of cyclooxygenase-1.
ТІАЗИНУРобота присвячена докінговому дослідженню механізму дії потенційного нестероїдного протизапального агента імідазотіазинового типу -3-[(3,5-дихлорпіридин-2-іл)окси]-3,4-дигідро-2H-бензо[4,5]імідазо [2,1-b][1,3] тіазину. Синтезована сполука 4q з наперед встановленою високою антиоксидантною активністю була досліджена на стикування однієї молекули відносно іншої -молекулярний докінг Проведеним експериментом встановлено, що в основі механізму протизапальної активності 4q лежить неселективний вплив на циклооксигенази першого та другого типу. Згідно з результатами моделювання стикування, наявність атома хлору у молекулі 4q створює додаткову гідрофобну взаємодію, що збільшує сумарну енергію зв 'язування. Докінговими дослідженнями виявлено, що 3-[(3,5-дихлорпіридин-2-іл)окси]-3,4-дигідро-2H-бензо[4,5]
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.